Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.
详细描述
This is a Cross-Sectional Study
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 25 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with Type 2 Diabetes for >5 years
- •Using Diabetes medications (metformin, sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors) for a period of 2-3 years
排除标准
- •Gestational Diabetes
- •Type 1 Diabetes
- •Severe non-proliferative diabetic retinopathy (NPDR) at baseline
- •Proliferative diabetic retinopathy (PDR) at baseline
- •Pregnant and breastfeeding women
研究者
Sara A Belal
Demonstrator at Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Alexandria University
Alexandria University